Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation

Traditional risk-adjusted valuation methods in the biotechnology industry exhibit significant limitations when assessing early-stage technologies. These limitations include high failure rates, lengthy development timelines, and substantial research and development (R&D) and commercialization costs, which traditional methods fail to fully incorporate. In this study, we propose a revised valuation methodology, 'modified risk-adjusted NPV' (mrNPV), which addresses R&D costs, probability of success, projected sales, timely risk application, and the cost of failure. The mrNPV method assesses the value of a diabetic drug under development as more than US$3 billion and free cash flow as more than US$300 million compared with the traditional method, demonstrating its applicability in biotechnology valuation and bridging the gap between theoretical frameworks and real-world needs.